These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells. Shimo T; Kurebayashi J; Kanomata N; Yamashita T; Kozuka Y; Moriya T; Sonoo H Breast Cancer; 2014 Jan; 21(1):75-85. PubMed ID: 22454224 [TBL] [Abstract][Full Text] [Related]
23. Olaparib for the treatment of metastatic prostate cancer. Dror CM; Wyatt AW; Chi KN Future Oncol; 2021 Jul; 17(19):2413-2429. PubMed ID: 33769071 [TBL] [Abstract][Full Text] [Related]
24. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer. Ivy SP; Liu JF; Lee JM; Matulonis UA; Kohn EC Expert Opin Investig Drugs; 2016; 25(5):597-611. PubMed ID: 26899229 [TBL] [Abstract][Full Text] [Related]
25. Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression. Ma X; Dang C; Min W; Diao Y; Hui W; Wang X; Dai Z; Wang X; Kang H Breast Cancer Res Treat; 2019 Jul; 176(1):109-117. PubMed ID: 30989461 [TBL] [Abstract][Full Text] [Related]
26. Combination of talaporfin photodynamic therapy and Poly (ADP-Ribose) polymerase (PARP) inhibitor in gastric cancer. Tanaka M; Sasaki M; Suzuki T; Nishie H; Kataoka H Biochem Biophys Res Commun; 2021 Feb; 539():1-7. PubMed ID: 33388624 [TBL] [Abstract][Full Text] [Related]
27. Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma. Ning J; Wakimoto H; Peters C; Martuza RL; Rabkin SD J Natl Cancer Inst; 2017 Mar; 109(3):1-13. PubMed ID: 28376211 [TBL] [Abstract][Full Text] [Related]
28. Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells. Nowsheen S; Cooper T; Stanley JA; Yang ES PLoS One; 2012; 7(10):e46614. PubMed ID: 23071597 [TBL] [Abstract][Full Text] [Related]
29. PARP inhibitors in castration-resistant prostate cancer. Tripathi A; Balakrishna P; Agarwal N Cancer Treat Res Commun; 2020; 24():100199. PubMed ID: 32745972 [TBL] [Abstract][Full Text] [Related]
30. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint. Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437 [TBL] [Abstract][Full Text] [Related]
31. Poly ADP Ribose Polymerase Inhibitor Olaparib Targeting Microhomology End Joining in Retinoblastoma Protein Defective Cancer: Analysis of the Retinoblastoma Cell-Killing Effects by Olaparib after Inducing Double-Strand Breaks. Jiang Y; Yam JC; Chu WK Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639028 [TBL] [Abstract][Full Text] [Related]
32. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside. Turk AA; Wisinski KB Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759 [TBL] [Abstract][Full Text] [Related]
33. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy]. Schreiber V; Illuzzi G; Héberlé E; Dantzer F Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693 [TBL] [Abstract][Full Text] [Related]
34. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer. Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466 [TBL] [Abstract][Full Text] [Related]
35. PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non-small-cell lung cancer. Jiang Y; Dai H; Li Y; Yin J; Guo S; Lin SY; McGrail DJ Int J Cancer; 2019 Mar; 144(5):1092-1103. PubMed ID: 30152517 [TBL] [Abstract][Full Text] [Related]
36. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib. Miller RE; Ledermann JA Clin Adv Hematol Oncol; 2016 Aug; 14(8):619-27. PubMed ID: 27487106 [TBL] [Abstract][Full Text] [Related]
37. TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. Tung NM; Robson ME; Ventz S; Santa-Maria CA; Nanda R; Marcom PK; Shah PD; Ballinger TJ; Yang ES; Vinayak S; Melisko M; Brufsky A; DeMeo M; Jenkins C; Domchek S; D'Andrea A; Lin NU; Hughes ME; Carey LA; Wagle N; Wulf GM; Krop IE; Wolff AC; Winer EP; Garber JE J Clin Oncol; 2020 Dec; 38(36):4274-4282. PubMed ID: 33119476 [TBL] [Abstract][Full Text] [Related]
38. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer. Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272 [TBL] [Abstract][Full Text] [Related]
39. BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell Lines. Shen YT; Evans JC; Zafarana G; Allen C; Piquette-Miller M Mol Pharm; 2018 Jul; 15(7):2742-2753. PubMed ID: 29750868 [TBL] [Abstract][Full Text] [Related]
40. The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others. Chen Y; Du H Biomed Pharmacother; 2018 Mar; 99():552-560. PubMed ID: 29895102 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]